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ARTICLE
Genotype to phenotype correlations in cartilage
oligomeric matrix protein associated
chondrodysplasias
Michael D Briggs*,1, Joanne Brock2, Simon C Ramsden2 and Peter A Bell1
Pseudoachondroplasia (PSACH) and autosomal dominant multiple epiphyseal dysplasia (MED) are chondrodysplasias resulting
in short-limbed dwarfism, joint pain and stiffness and early onset osteoarthritis. All PSACH, and the largest proportion of MED,
result from mutations in cartilage oligomeric matrix protein (COMP). The first mutations in COMP were identified in 1995 in
patients with both PSACH and MED and subsequently there has been over 30 publications describing COMP mutations in at
least 250 PSACH–MED patients. However, despite these discoveries, a methodical analysis of the relationship between COMP
mutations and phenotypes has not been undertaken. In particular, there has, to date, been little correlation between the type
and location of a COMP mutation and the resulting phenotype of PSACH or MED. To determine if genotype to phenotype
correlations could be derived for COMP, we collated 300 COMP mutations, including 25 recently identified novel mutations.
The results of this analysis demonstrate that mutations in specific residues and/or regions of the type III repeats of COMP are
significantly associated with either PSACH or MED. This newly derived genotype to phenotype correlation may aid in
determining the prognosis of PSACH and MED, including the prediction of disease severity, and in the long term guide genetic
counselling and contribute to the clinical management of patients with these diseases.
European Journal of Human Genetics (2014) 22, 1278–1282; doi:10.1038/ejhg.2014.30; published online 5 March 2014
INTRODUCTION
Pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia
(MED) are relatively common chondrodysplasias resulting in joint
pain and stiffness, short-limbed dwarfism and in many cases early
onset osteoarthritis.1 PSACH results exclusively from mutations in
cartilage oligomeric matrix protein (COMP),2 a large pentameric
glycoprotein found in cartilage, tendon, ligament and skeletal
muscle.3 In contrast, autosomal dominant MED is genetically
heterogeneous and although in the European population the largest
proportion results from COMP mutations, other forms of MED can
be caused by mutations in the genes encoding matrilin-3 (MATN3)
and type IX collagen (COL9A1, COL9A2 and COL9A3).2,4 Both of
these proteins are known to interact with COMP in the cartilage
extracellular matrix and help coordinate collagen fibrillogenesis.
Autosomal recessive MED appears to result exclusively from
mutations in sulphate transporter solute carrier family 26.2
Despite consistent genotype to phenotype correlations across the
various genes; that is, COMP (PSACH or MED), MATN3 (MED
only) and type IX collagen (MED only),2 there has been no systematic
investigation of the relationship between COMP mutations and
phenotype (PSACH or MED). In particular, there has been no
study on the type and location of a COMP mutation and the
resulting phenotype.
To address this omission, we collated a comprehensive list of
COMP mutations and the resulting phenotypes from 300 individual
case reports that were published between 1995 and 2012 (n¼ 260) or
recently identified as part of our diagnostic service for PSACH and
MED (n¼ 40). The reported mutations were from 32 different
publications, although the majority (n¼ 183) had been described in
seven articles, and our unreported cases formed the third largest
cohort and included 25 novel COMP mutations.2,4–9 To promote the
clinical utility of any genotype to phenotype correlations and provide
a realistic appreciation of the clinical-diagnostic process, we recorded
the phenotypes as originally reported, without any further review,
which would provide a more robust model should significant
correlations be identified.
MATERIALS AND METHODS
Mutation analysis
For the novel mutations reported in this study, mutational analysis of the
COMP gene was performed as previously described.5 Briefly, bidirectional
fluorescent sequence analysis was used to screen for mutations in exons 8–19
of COMP including the splice donor and acceptor sites. COMP nomenclature
is according to Genebank Accession number NM_000095.2 with nucleotide 1
as the first nucleotide of translation. Mutations are accessible in the Human
Mutation Database and Leiden Open Variation Database.
Statistical analysis
The Fisher exact test was used to test the following null hypotheses:-
1. That no association exists between the location of a mutation within the T3
repeats of COMP and the frequency of PSACH versusMED diagnosis; that is,
the frequency of PSACH versus MED missense mutations reported for each
T3 repeat was compared with the total frequency of PSACH versus MED
mutations reported in all other COMP T3 repeats (Supplementary Table 2).
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2. That no association exists between the location of a mutation within the
N- versus C- type motifs of the T3 repeats and the frequency of PSACH
versus MED diagnosis.
In all statistical analyses, cases in which mutations did not lead to a defined
MED or PSACH diagnosis were excluded and the null hypothesis was rejected
upon calculation of a P-value o0.05.
RESULTS
Domain-specific distribution of COMP mutations
In the first instance, we examined the domain-specific locations of the
300 mutations (Table 1 and Supplementary Table 1). Three putative
mutations (1%) were identified in the type II (EGF-like) repeat
domain (T2-COMP), 269 mutations (90%) in the type III repeat
domain (T3-COMP) and 28 mutations (9%) in the carboxyl-terminal
domain (CTD-COMP), thereby confirming that both PSACH and
MED mutations are predominantly located within the type III repeat
domain of COMP.
Missense mutations in the type II repeats of COMP have
unresolved pathogenicity
Recently, putative missense mutations in three of the four type 2
(EGF-like) domains have been identified (c.500G4A p.(Gly167Glu)),
(c.700C4T p.(Pro234Ser)) and (c.772G4C p.(Gly258Arg)) (Table 1;
Supplementary Table 1 and 2); however, the scarcity of these mutations
and their unresolved pathogenicity makes any correlations of limited
clinical value, although they do appear to cause a range of phenotypes
within the MED to mild PSACH disease spectrum, but without any
distinguishing features.2
Missense mutations in the type III repeats are the major cause of
PSACH & MED and show significant phenotypic correlations
The type III repeat region of COMP comprises of amino acid residues
268–528 (n¼ 261) arranged into eight consecutive T3 repeats typified
by a consensus motif that is characteristic of a calcium-binding pocket
(Figure 1). Six of the T3 repeats (T31, T32, T34, T36, T37 and T38)
have both N- and C-type motifs, whereas T33 and T35 only have a
single C-type motif. In addition to the repetitive nature of this
domain, it is also composed of a high proportion of specific residues
such aspartic acid, glycine, cysteine, asparagine and proline that have
important roles in protein folding and calcium binding.
In total, 179 missense mutations have been identified in 73 of the
261 codons (28%) that comprise the T3 domain. Fifty three of these
73 codons (73%) encode amino acid residues that comprise the
consensus motifs of the individual repeats, thereby confirming the
importance of these residues for the correct folding and/or functioning
of this domain. Of the remaining 20 codons, 11 encode residues such
as cysteine, aspartic acid, proline and glycine, which also have
potentially important roles in protein folding. Overall, this clustering
suggests that the primary sequence of COMP is very highly restrained;
indeed, only a single non-synonymous polymorphism (c.1156A4G
p.(Asn386Asp)) has been regularly identified in the type III repeat
region. We therefore hypothesised that the large number of missense
mutations and high degree of amino acid similarity within the
individual repeats would provide an ideal opportunity to derive, for
the first time, phenotype to genotype correlations for PSACH
and MED.
We firstly determined that there was no significant association
between the incidence of MED and PSACH causing missense
mutations and whether the mutation occurred within the N- or
C-type motifs of the T3 repeats of COMP (P¼ 0.403). We next
compared the frequency of PSACH versus MED missense mutations
in each of the T3 repeats, to determine whether a mutation within a
given T3 repeat is more associated with PSACH or MED
(Supplementary Table 2).
There was no significant association between phenotype and
mutation in T31 (P¼ 0.0524), with 14 PSACH mutations compared
with five MED mutations. Likewise, mutations in the T32 (P¼ 0.32)
and T33 (P¼ 1.00) repeats also showed no significant association with
a specific phenotype.
In contrast, T34 showed a very significant association with MED
compared with the other T3 repeats (Po0.0001). Indeed, it was
obvious that (c.1153G4A p.(Asp385Asn)) that had been identified in
14 patients with MED was influencing this association. However,
it was also clear that a contiguous stretch of MED-associated
mutations were present in both the N- and C-type motifs of the
T34 repeat and of the 33 mutations in nine codons, 27 were reported
to have caused MED, whereas the mutation of aspartic acid at residue
376 was associated with MED in three cases and a single PSACH
patient. Finally, (c.1159T4G p.(Cys387Gly)) and (c.1159T4C
p.(Cys387Arg)) caused PSACH in two cases, which was comparable
to the substitution of a cysteine residue at equivalent locations in the
C-type motifs of the other T3 repeats.
Similarly, mutations in T35 were also very significantly associated
with a greater frequency of MED compared with mutations in
other T3 repeats (P¼ 0.0009). For example, mutations in eight of
the nine codons are associated with MED (n¼ 13 cases), whereas
Table 1 Novel COMP mutations
Phenotype Exon DNA change Protein change Domain
PSACH 8 c.772G4C p.(Gly258Arg) EGF4
PSACH 8 c.806A4G p.(Asp269Gly) T31
PSACH 8 c.806A4G p.(Asp269Gly) T31
PSACH 8 c.818A4C p.(Asp273Ala) T31
MED 9 c.886C4A p.(Pro296Thr) T31
MED 9 c.935G4A p.(Cys312Tyr) T32
PSACH/MED 10 c.1032_1034del p.(Trp344_Gly345delinsCys) T33
MED 10 c.1034G4A p.(Gly345Asp) T33
MED 10 c.1044C4G p.(Cys348Trp) T33
MED 10 c.1126G4A p.(Asp376Asn) T34
MED 10 c.1133A4T p.(Asp378Val) T34
MED 11 c.1201G4T p.(Asp401Tyr) T35
MED 11 c.1222G4A p.(Asp408Asn) T35
MED 12 c.1280G4C p.(Gly427Ala) T36
MED 13 c.1317C4A p.(Asp439Glu) T36
PSACH 13 c.1336G4C p.(Asp446His) T36
PSACH 13 c.1359C4A p.(Asn453Lys) T36
PSACH 13 c.1394G4A p.(Gly465Asp) T37
PSACH 13 c.1414G4C p.(Asp472His) T37
PSACH 13 c.1420_1425dup p.(Asn474_Asp475dup) T37
MED 13 c.1467C4A p.(Asn489Lys) T37
PSACH 14 c.1510T4C p.(Cys504Arg) T38
PSACH 14 c.1531G4T p.(Asp511Tyr) T38
PSACH 14 c.1533C4G p.(Asp511Glu) T38
MED 16 c.1754C4A p.(Thr585Lys) CTD
Abbreviations: COMP, cartilage oligomeric matrix protein; CTD, carboxyl-terminal domain; MED,
multiple epiphyseal dysplasia; PSACH, pseudoachondroplasia; T2-EGF4, epidermal growth
factor (EGF) repeat of the type COMP region; type T3, type 3 repeat region of COMP.
The details of 25 novel COMP mutations identified as a part of this study. Exon numbering is
from NG_007070.1 and the gene nomenclature is classified according to Genebank accession
number NM_000095.2 for COMP with nucleotide 1 as the first nucleotide of translation.
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(c.1229G4A p.(Cys410Tyr)) appears to cause the borderline pheno-
type of MED or mild PSACH (n¼ 3).
Missense mutations in T36, T37 and T38 were significantly
associated with a greater frequency of PSACH compared with
mutations in other T3 repeats (P¼ 0.0156, P¼ 0.0097, P¼ 0.0384,
respectively), which therefore identified this region in COMP as
‘PSACH-specific’. This significant association did not even take
account of the common PSACH (c.1417_1419delGAC p.(D469del))
mutation (present in 16% of all patients in this study), but it was clear
that missense mutations at several key residues were contributing to
this association. These included various mutations affecting the
following residues: glycine 440 (n¼ 9); aspartic acid 473 and
asparagine 518 (n¼ 6 each); glycine 465 (n¼ 5 each); glycine 446,
aspartic acid 509 and aspartic acid 511 (n¼ 4 each), which all caused
PSACH. Interestingly, different nucleotide transversions or transitions
at codons 465, 473, 482 and 518 individually caused three or four
different amino acid substitutions at each codon (Table 2).
Missense mutations in CTD show distinct clustering in functional
motifs
CTD-COMP mutations were reported in 28 cases of PSACH and
MED and therefore represent a minor cause of these diseases
(o10%). However, these are still functionally relevant mutations
and as previously reported, they cluster in distinct regions of this
domain.10 In particular, the mutation of codons 583, 585 and 587
define the first region, whereas mutation of codons 718 and 719
define a second region. Furthermore, (c.2153G4C p.(Arg718Pro))
and (c.2152C4T p.(Arg718Trp)), which always causes MED, were
reported in 10/28 cases (B36%), whereas substitution of the
neighbouring residue (c.2155G4A p.(Arg719Ser)) and (c.2156G4A
Figure 1 An illustration of the type III repeat region of COMP and the location of missense mutations and in-frame deletions, insertions or indels that lead
to PSACH and/or MED. Each of the eight type III repeats are indicated on the left (T31, T32 etc.) along with the number of the COMP residue at the start
of each repeat. The N- and C-type motifs are shown at the top and the residues that comprise each motif are boxed. The consensus sequence for the
N- and C-type motifs are shown below. Residues that have missense mutations which cause MED are coloured GREEN, those that cause PSACH are
coloured RED and mutations reported to cause both PSACH and MED are coloured BLUE. In-frame deletions, insertions or indels are double underlined
using the same PSACH–MED colour scheme. The number of patients with a missense mutation identified at each codon is indicated above the relevant
residue. Missense mutations in blocks of COMP residues that cause MED are highlighted in blue and those that cause PSACH are highlighted in green.
Table 2 Multiple mutations in individual codons
Residue number DNA change Protein change Phenotype
465 c.1393G4C p.(Gly465Arg) PSACH
c.1393G4A p.(Gly465Ser) PSACH
c.1394G4A p.(Gly465Asp) PSACH
c.1394G4T p.(Gly465Val) PSACH
473 c.1417G4T p.(Asp473Tyr) PSACH
c.1417G4A p.(Asp473Asn) PSACH
c.1417G4C p.(Asp473His) PSACH
c.1418A4G p.(Asp473Gly) PSACH
482 c.1444G4A p.(Asp482Asn) MED
c.1444G4C p.(Asp482His) PSACH
c.1445A4G p.(Asp482Gly) PSACH
518 c.1552G4A p.(Asp518Asn) PSACH
c.1552G4C p.(Asp518His) PSACH
c.1553A4G p.(Asp518Gly) PSACH
Abbreviaitions: MED, multiple epiphyseal dysplasia; PSACH, pseudoachondroplasia.
The details of mutations found at four COMP codons that result in the substitution of at least
three different amino acids. Exon gene nomenclature is classified according to Genebank
accession number NM_000095.2 for COMP with nucleotide 1 as the first nucleotide of
translation.
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p.(Arg719Asp)) causes PSACH (n¼ 3; B11%). Interestingly, the
other common CTD-COMP mutation at residue 585 (c.1754C4T
p.(Thr585Met); c.1754C4G p.(Thr585Arg) and c.1754C4A
p.(Thr585Lys); n¼ 6; B21%) often causes a transitional phenotype
of mild PSACH to severe MED9 and the association of mild
myopathy with CTD-COMP mutations is well documented.3
In-frame deletions, insertions and indels are significantly
associated with PSACH
Regardless of the specific COMP genomic DNA mutation, all the
deletions, insertions and indels cause in-frame alterations to the
COMP protein primary sequence and no frame shifts have been
identified with one exception,11 which we did not include in this
study as our focus was on qualitative protein defects. In total, there
were 90 (30%) instances of these classes of mutations and therefore,
it represented significant cause of abnormal COMP synthesis.
The majority of in-frame deletions, insertions or indels lead to
PSACH (n¼ 74; 82%), whereas a smaller proportion causes MED
(n¼ 16; 18%); however, in several instances, the same mutation was
reported to cause both PSACH and MED. The high incidence of these
classes of mutations is influenced by the deletion of a single aspartic
acid residue (c.1417_1419delGAC p.(Asp473del)) from a contiguous
stretch of five aspartic acid codons (GAC) encoding residues 469 to
473 of COMP, which has been reported in numerous studies to be a
common mutation in PSACH. This observation was further corro-
borated by this study, which confirmed that (c.1417_1419delGAC
p.(Asp473del)) accounted for 49 cases of PSACH and was the most
common mutation in the entire series (16%).
Interestingly, more complex mutations are also found within this
repeated region and includes the deletion of either two or three
GAC codons (c.1414_1419delGACGAC p.(Asp472_Asp473del)) and
(c.1411_1419delGACGACGAC p.(Asp471_Asp473del)) that cause PSACH
(n¼ 3), the duplication of single GAC codon (c.1417_1419dup
p.(Asp473dup)) that consistently causes MED (n¼ 4) and the dupli-
cation of two GAC codons (c.1414_1419dup p.(Asp472_Asp473dup))
that causes PSACH (n¼ 2).
Other notable ‘hot-spots’ for these classes of mutations include
(c.1120_1122del p.(Asp374del)) or (c.1117_1122del p.(Asp373_Asp374-
del)) (n¼ 5), (c.1021_1026del p.(Glu341_Asp342del)) (n¼ 4) and
(c.1170_1181delinsTGT p.(Pro391_Asp394delinsVal)) (n¼ 2), which
most often cause PSACH, with the exception of two cases reported as
MED by Kim et al 2011.4 Interestingly, (c.1371_1373del p.(Glu457del))
appears to result equally in PSACH (n¼ 2) or MED (n¼ 3), although
a revaluation of the available clinical information would suggest that
presentation is at the severe end of the MED spectrum. The remaining
15 cases of this type of mutation have only been reported in single
cases and can result in a range of phenotypes within the PSACH
and MED disease spectrum, although the majority cause PSACH
(n¼ 10; B67%).
DISCUSSION
Even though the first COMP mutations were identified in PSACH
and MED patients nearly 20 years ago, there has been no compre-
hensive genotype to phenotype correlation derived to date. The
compilation and analysis of 300 cases in this study has allowed us to
redress this oversight and to identify some important correlations that
may assist in genetic counselling and disease prognosis.
The large number of missense mutations that have been identified
in the type III repeats allowed us to derive the first genotype to
phenotype correlation for COMP and this provides strong evidence
for both PSACH- and MED-associated regions. For example, it was
clear that a missense mutation in the residues encompassing T34 and
T35 was more likely to result in MED, whereas mutations in T36–T38
were generally associated with PSACH. One notable correlation was
the substitution of cysteine residues comprising the invariant position
14 of the C-type motif consensus sequence that causes PSACH
(Cys328, n¼ 2; Cys351, n¼ 3; Cys387, n¼ 2; Cys448, n¼ 1; Cys484,
n¼ 1) in all but one position (Cys410, n¼ 3). This latter finding
highlights the potential importance of these cysteine residues to the
folding of the C-type motif of COMP.
It is clear that the vast majority (480%) of in-frame deletions,
insertions or indels cause PSACH because these mutations are
presumably more likely to cause a greater disruption to the folding
and tertiary structure of the COMP protein. The high incidence of in-
frame deletions, insertions or indels in the type III repeat region of
COMP is most likely due to the repetitive nature of the DNA within
the exons encoding this protein domain. To date, no in-frame
deletions, insertions or indels have been identified in the carboxyl-
terminal globular domain.
The deletions and insertions of Asp473 and the neighbouring
residues are themselves an interesting group of mutations.
p.(Asp473del) is the most common COMP mutation (n¼ 49/300)
and always causes severe PSACH, along with the deletion of either two
or three GAC codons (p.(Asp472_Asp473del) and p.(Asp471_Asp473-
del)) (n¼ 3/300). In contrast, the duplication of a single GAC codon
p.(Asp473dup) consistently causes MED (n¼ 4/300), whereas the
duplication of two GAC codons p.(Asp472_Asp473dup) causes
PSACH (n¼ 2/300). These correlations in phenotypic presentation
suggest that the deletion of a single aspartic acid residue disrupts the
consensus calcium-binding pocket of the C-type motif of the T36
repeat to a greater extent than the insertion of a single aspartic acid.
However, the insertion of two aspartic acid residues again has a more
detrimental effect on calcium binding and protein folding, which are
not mutually exclusive. It has previously been proposed that these
insertions are examples of trinucleotide expansion mutations,12 but
there is no evidence of genetic anticipation in PSACH–MED through
an increased expansion of the GAC triplets and they are likely to be
self-limiting mutations.
For 10 missense mutations and a single deletion that had been
identified in more than one patient each, the phenotype had been
recorded as either PSACH or MED. The discrepancies in diagnosis
reflect the challenge in diagnosing these diseases and highlights the
phenotypic overlap between MED and mild PSACH.13 It remains
highly possible that genetic modifiers of phenotypic severity are likely
to influence disease severity, which has already been reported for
MED caused by MATN3 mutations.14
In conclusion, we have collated 300 COMP mutations that cause
PSACH and MED and have derived the first genotype to phenotype
correlations. Although there are significant associations with some
residues, particularly those with 43 reported mutations, others are
less clear, and extra factors (such as diagnostic interpretation and
genetic modifiers) may have an influence. Nevertheless, this study
provides a first framework that may help medical professionals in
predicting phenotype and/or disease severity.
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